Once Daily Dose (ODD) Lorazepam (Lo) for Seizure Prophylaxis in Conjunction with Once Daily Dose Busulfan (BU) for Pediatric Patients Undergoing Reduced Intensity Conditioning (RIC) for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)  by Shinkle, M. et al.
Oral Presentations S241previously reported aHSCT patients take a median of 17 (range 3-
49) medications daily at Mayo Clinic. This study aimed to determine
if medication burden correlates with quality of life (QoL) at 1 year
following HSCT.
Methods: As part of an ongoing, IRB approved QoL study we ex-
amined the cross-sectional relationship between medication burden
and QoL among all adult aHSCT patients with adequate documen-
tation and follow-up between 7/1/09 and 9/30/10. Medication bur-
den was assessed by number of scheduled medications, maximum
possible doses and maximum possible pills per day reconciled by
a pharmacist pre-HSCT and 1 year post-HSCT. QoL was assessed
by the Functional Assessment of Cancer Therapy (FACT)-General
(version 4) during pre-HSCT evaluation and FACT-BMT 1 year
post-HSCT.
Results: During the study period, 57 patients received an aHSCT
and enrolled in the QoL study; 43 patients were included. Patients
were excluded for death before 1 year (n 5 13), incomplete medi-
cation record (n 5 1), missing post-HSCT QoL data (n 5 2). Me-
dian patient age was 55 years (range of 24-71); 50% of patients
were male and most patients had an ECOG performance score of
0 or 1 (n 5 1 ECOG of 2). Pre-HSCT total scheduled pills per
day negatively correlated with social well being. Pre-HSCT,
a higher number of maximum possible pills per day (scheduled
and prn) was associated with worse pre-transplant QoL across do-
mains of physical, social, functional, and overall well-being. The as-
sociations with physical, social, and total well-being remained
significant after adjustment for age, gender, and ECOG perfor-
mance score. A higher pre-HSCT maximum possible pills per
day correlates with worse physical and overall well being 1-year
post-HSCT. Post-transplant a higher number of maximum possi-
ble pills per day negatively correlated with physical, functional,
and overall well-being 1 year post-transplant, even after covariate
adjustment.
Conclusion: These data offer preliminary evidence that maximum
daily pill count (scheduled and prn) might be a significant predictor
of QoL among HSCT recipients. Better understanding of which as-
pects of medication burden (e.g., pill count, medication type) affect
domains of QoLmay help identify possible medication management
strategies to improve QoL.102
EFFECT OF CYTOXAN DOSING ON HEMATOPOIETIC STEM CELL (HSC)
MOBILIZATION EFFICACY, TOXICITY, AND COST IN SUCCESSIVE CO-
HORTS OF NON-HODGKIN’S LYMPHOMA (NHL) PATIENTS
Sanacore, M.F.1, Sizemore, C.A.1, Xhang, X.2, Schipani, B.1,
Morris, L.E.1, Bashey, A.1, Holland, H.K.1, Solomon, S.R.1 1Blood and
Marrow Transplant Program at Northside Hospital, Atlanta, GA; 2Geor-
gia State University, Atlanta, GA
Background:Cyclophosphamide (Cy) has been shown to be an ef-
fective regimen for HSC mobilization in NHL patients undergoingTable.
Cy2 (n 5 28) Cy3 (n 5 31) Cy4 (n 5 28
Collect $2x106 in #2 days 39% 87% 82%
Collect$5x106 in #2 days 14% 42% 46%
Collect$5x106 in all days 18% 45% 64%
Collect$2x106 in all days 89% 100% 100%
Median # of collections 3 2 2
% Patients hospitalized for FN 0% 16% 32%
Hospitalization Days (median) 0 3 4
Days of G-CSF (median) 11.5 12.5 10.5
% Pts receiving plerixafor 32% 42% 4%
Relative Mobilization Cost
(normalized to Cy4)
1.47 1.37 1.00autologous stem cell transplantation (ASCT). However, the opti-
mal dose to be used, which maximizes HSC collection yields while
minimizing febrile neutropenia and other toxicities, remains con-
troversial. Three successive cohorts of NHL patients who received
G-CSF and Cy at doses of either 4g/m2 (Cy4), 2g/m2 (Cy2) or 3g/
m2 (Cy3) were compared.
Methods: 31 pts undergoing Cy3 mobilization between October
2009 and August 2011 were retrospectively analyzed and com-
pared to our historical Cy2 (n 5 28) and Cy4 (n 5 28) data.
Minimal and optimal yield was defined as collection of $2 x
106 and $5 x 106 CD34+ cells/kg, respectively. Apheresis was
initiated utilizing WBC and CD34+ cell count to guide start of
collection and preemptive plerixafor use, whereas in historical
Cy4 and Cy2 cohorts, plerixafor was only used following mobi-
lization failure.
Results:Minimal cell dose required for ASCT was achieved in the
majority of patients in all groups (89%, 100% and 100% of Cy2, 3,
and 4 pts, respectively). However, the collection efficiency clearly
favored Cy3 and Cy4, with the proportion of patients collecting
$2 x 106 CD34+ cells/kg in 2 days being 87% and 82%, respec-
tively vs. 39% for Cy2 (p\0.001). In contrast, toxicity, as measured
by % febrile neutropenia and median hospitalization days, favored
Cy2 (0%, 0d) compared with Cy4 (32%, 4d, p 5 0.002), with Cy3
falling intermediate between these groups (16%, 3d). Requirement
for Plerixafor was significantly higher for both Cy2 (32%) and Cy3
(42%), compared with Cy4 (4%, p 5 0.003). Relative cost clearly
favored Cy4, when accounting for the combined costs of Cy, G-
CSF, plerixafor, hospitalization, and apheresis, with Cy3 and Cy2
costing approximately 37% and 47% more, respectively, per pa-
tient mobilization.
Conclusions: Although Cy2, 3, and 4 are all effective mobilizing
regimens, collection efficiency, toxicity, and cost vary greatly. Both
Cy3 and Cy4 improve collection efficiency, at the expense of in-
creased hospitalization, particularly with Cy4. Cy4 appears to max-
imize collection efficiency while minimizing plerixafor use and
overall cost. Further improvements in supportive care strategies to
reduce the incidence of febrile neutropenia and associated hospital-
ization are clearly needed.103
ONCE DAILY DOSE (ODD) LORAZEPAM (LO) FOR SEIZURE PROPHYLAXIS
IN CONJUNCTIONWITH ONCE DAILY DOSE BUSULFAN (BU) FOR PEDIAT-
RIC PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING (RIC)
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT)
Shinkle, M.1, Powers, K.1, Tobin, M.1, Kletzel, M.1,2 1Children’s Memo-
rial Hospital, Chicago, IL; 2Northwestern University Feinberg School of
Medicine, Chicago, IL
BU is an alkylating agent used as part of conditioning for
HSCT. It is known to cause seizures in the 3rd and 4th day of) P-value
Pairwise Comparison (significant if p-value<0.017
based on Bonferroni adjustment)
Cy2 vs Cy3 Cy2 vs Cy4 Cy3 vs Cy4
<0.001 <0.001 0.001 0.597
0.022 0.019 0.009 0.729
0.002 0.025 <0.001 0.141
n.s N/A N/A N/A
<0.001 <0.001 0.011 0.830
0.002 0.062 0.002 0.127
0.004 0.033 0.002 0.113
n.s N/A N/A N/A
0.003 0.437 0.005 <0.001
Table 1. Top 3 greatest challenges facingBMTnurses in today’s










Recruiting/hiring nurses 28% 12% 13% 59
Education/orientation of
new nurses
15% 21% 12% -
Staying abreast of scientific
advances in BMT
22% 25% 12% 63
Working in challenging/stressful
environment
56% 24% 8% 111
Meeting patients’ needs 18% 20% 17% -
Balancing demands of
work/personal life
20% 20% 19% 59
Resources for addressing
ethical/moral issues in BMT
12% 22% 20% -
TheWeighted Rank Score is equal to the sum of points for first, second
and third choice designations (first 5 1.00 point; second 5 0.66 point;
and third 5 0.33 point).
S242 Oral Presentationstherapy when given every 6 hours, requiring prophylaxis with
phenytoin. From 2003 to date, at Children’s Memorial Hospital
(CMH) we have a RIC regimen utilizing ODD targeted BU for
two days. In this protocol, the seizure prophylaxis has been low
ODD Lo (0.05mg/kg max 2mg) since 2005. A 0.8 mg/kg test
dose (TD) of BU infused over 3 hours is given 5-7 days prior to
the RIC. Pharmacokinetic data from blood samples during the
TD BU provided information on AUC and clearance. The
AUC from the TD BU is used to calculate the ODD of BU.
The ODD BU is infused over 3 hours on day -5 and -4 of the
HSCT. To determine if ODD Lo prophylaxis for RIC BU was
associated with a low incidence of seizures, a retrospective chart
review was preformed of 68 pediatric patients from CMH. These
patients were a subset of a prospective study of RIC (IV BU x 2
days, Fludarabine 30 mg/m2 x 5 days, 6 ATG/ECP) for HSCT
carried out between July 2003 and May 2008. 50 patients (1
month-21 years of age) received ODD Lo as seizure prophylaxis
prior to ODD BU. The average ODD BU AUC per day was
3126 umol/min (2912-7254) and the average daily dose was 3.3
mg/kg. These patients had no history of seizures and were on
no other anti-epileptic medications. No patients experienced a sei-
zure during their RIC utilizing ODD Lo prophylaxis. Indication
for HSCT was malignancy in 20 patients and non-malignant dis-
ease in 30 patients. This low dose/frequency approach to seizure
prophylaxis was not associated with an increased risk of seizures.
ODD Lo is a low cost option for seizure prophylaxis in ODD BU
RIC regimens and is aimed at limiting the sedation associated
with Lo while providing coverage during the time period BU is
highly detectable in the blood allowing for a better quality of
life for the patients, especially since many of the RIC HSCTs
are done as outpatients.TRANSPLANT NURSING ORAL:
ADMINISTRATION104
IDENTIFYING CHALLENGES TO THE FUTURE BMT NURSING WORK-
FORCE: HEMATOPOIETIC CELL TRANSPLANTATION IN 2020
Tierney, D.K.1, Sylvanus, T.2, De Kesel Lofthus, A.3, Denzen, E.M.3,
Murphy, E.A.3, Schmit-Pokorny, K.A.4, Neumann, J.5 1Stanford Uni-
versity Medical Center, Stanford, CA; 2University of South Florida,
Tamps, FL; 3National Marrow Donor Program, Minneapolis, MN;
4University of Nebraska Medical Center, Omaha, NE; 5University of
Texas, Houston, TX
Annually, more than 20,000 blood and marrow transplants
(BMT) are performed in the U.S. and this number is expected to
increase. Challenges to the future growth of BMT stem from the
projected nursing shortage, as identified in the 2010 IOM Report
on The Future of Nursing. The National Marrow Donor Pro-
gram sponsored the System Capacity Initiative (SCI) to assess
the ability to meet the increasing demand for BMT. The SCI con-
vened the Nursing Workforce Working Group (WG) which iden-
tified two priority challenges. The first is recruitment of BMT
nurses and the second is retention of nurses currently working in
the field.
Surveys were administered to members of the Oncology Nursing
Society and American Society of Blood andMarrowTransplantation
BMT nursing special interest groups between July and August 2010;
BMT nurses were also surveyed at the 2011 BMTTandemMeetings
(N 5 205). The survey objectives included:
– Characterize the current capacity of the U.S. BMT nursing
workforce
– Identify pathways through which nurses learned of and entered
the BMT specialty
– Assess satisfaction with the BMT specialty among nurses.
The survey was sent to an estimated 1,600 BMT nurses with
a response rate of 13% (N 5 205). Among respondents, 67% in-
dicated that their institution was planning to increase the numberof transplants performed annually. Respondents identified the
greatest challenges facing the BMT Nursing Workforce (Table 1).
In the next 5 years, many BMT nurses plan to advance their
level of nursing degree (66%); change roles within BMT (48%); re-
duce the number of hours worked (36%); and change specialties
(22%).
Based on survey results, the WG initiated programs to pro-
mote BMT nursing as a career choice and to identify stressors
and challenges in BMT nurses’ work environments that contrib-
ute to compassion fatigue and job attrition. Interest in exposing
nursing students to BMT was explored via interview at Loma
Linda Hospital and School of Nursing. An Introduction to
BMT outreach presentation was developed, targeting BSN
students.
The WG will continue to develop strategies to overcome recruit-
ment and retention challenges by developing an interdisciplinary
rounds model to address moral distress and compassion fatigue
among BMT nurses and targeted messaging for outreach to diverse
nursing communities of interest.105
IMPROVING THE QUALITY OF CARE DELIVERED TO HEALTHY RELATED
DONORS: IMPLEMENTATION OF A RELATED DONOR TEAM
Sharf, S.E.S., Friedman, A., Sharf, A., Kasow, K.A. University of North
Carolina at Chapel Hill, Chapel Hill, NC
Allogeneic donor safety remains a primary cornerstone of the
UNC Bone Marrow and Stem Cell Transplant Quality Manage-
ment Program (QMP). Requirements for the safety of the do-
nor, recipient and the cellular therapy product are detailed in
the FACT Cellular Therapy Standards and the FDA’s Good
Tissue Practice Act. To insure compliance with regulations
and donor safety, continually evaluating the care delivered to re-
lated donors is a high-priority quality initiative for our program.
During 2009-2011, our QMP audited all related donor charts
for compliance of the following: review of the health history
questionnaire, pertinent positives noted in the donor’s medical
record (MR), and required laboratory evaluations. Audits also
assessed for documentation of the physical exam, assessment
of venous access, donor’s signature on the ‘‘Release of Medical
Records’’ form, pregnancy assessment, donor eligibility in the
donor and recipient’s MR, and review of abnormal results
with the donor including follow-up recommendations. Audits
were performed biannually in 2009 and 2010 and quarterly
in 2011. Data is presented in aggregate for each year. 62
